366 related articles for article (PubMed ID: 12381232)
1. Danaparoid: a review of its use in thromboembolic and coagulation disorders.
Ibbotson T; Perry CM
Drugs; 2002; 62(15):2283-314. PubMed ID: 12381232
[TBL] [Abstract][Full Text] [Related]
2. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
Wilde MI; Markham A
Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
[TBL] [Abstract][Full Text] [Related]
3. Danaparoid sodium.
Acostamadiedo JM; Iyer UG; Owen J
Expert Opin Pharmacother; 2000 May; 1(4):803-14. PubMed ID: 11249517
[TBL] [Abstract][Full Text] [Related]
4. Danaparoid in the prevention of thromboembolic complications.
Skoutakis VA
Ann Pharmacother; 1997; 31(7-8):876-87. PubMed ID: 9220051
[TBL] [Abstract][Full Text] [Related]
5. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures.
Kodityal S; Manhas AH; Udden M; Rice L
Eur J Haematol; 2003 Aug; 71(2):109-13. PubMed ID: 12890149
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of danaparoid compared with enoxaparin as deep vein thrombosis prophylaxis after hip replacement surgery.
Wade WE
Am J Orthop (Belle Mead NJ); 1999 Apr; 28(4):229-31. PubMed ID: 10220094
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients.
Polkinghorne KR; McMahon LP; Becker GJ
Am J Kidney Dis; 2002 Nov; 40(5):990-5. PubMed ID: 12407644
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
Tardy-Poncet B; Tardy B; Reynaud J; Mahul P; Mismetti P; Mazet E; Guyotat D
Chest; 1999 Jun; 115(6):1616-20. PubMed ID: 10378558
[TBL] [Abstract][Full Text] [Related]
9. The management of heparin-induced thrombocytopenia.
Keeling D; Davidson S; Watson H;
Br J Haematol; 2006 May; 133(3):259-69. PubMed ID: 16643427
[TBL] [Abstract][Full Text] [Related]
10. The effect of danaparoid sodium (danaparoid) on endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats.
Fujishima Y; Yokota K; Sukamoto T
Thromb Res; 1998 Sep; 91(5):221-7. PubMed ID: 9755834
[TBL] [Abstract][Full Text] [Related]
11. Ardeparin and danaparoid for prevention of deep vein thrombosis.
Med Lett Drugs Ther; 1997 Oct; 39(1011):94-5. PubMed ID: 9379998
[No Abstract] [Full Text] [Related]
12. A comparison of danaparoid and warfarin for prophylaxis against deep vein thrombosis after total hip replacement: The Danaparoid Hip Arthroplasty Investigators Group.
Comp PC; Voegeli T; McCutchen JW; Skoutakis VA; Trowbridge A; Overdyke WL
Orthopedics; 1998 Oct; 21(10):1123-8. PubMed ID: 9801236
[TBL] [Abstract][Full Text] [Related]
13. Successful use of danaparoid in treatment of heparin-induced thrombocytopenia during twin pregnancy.
Gill J; Kovacs MJ
Obstet Gynecol; 1997 Oct; 90(4 Pt 2):648-50. PubMed ID: 11770579
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Danaparoid Sodium and Synthetic Protease Inhibitors for the Treatment of Disseminated Intravascular Coagulation Associated with Hematological Malignancies: A Retrospective Analysis.
Minakata D; Fujiwara SI; Hayakawa J; Nakasone H; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Sugimoto M; Ishihara Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Ohmori T; Kanda Y
Acta Haematol; 2020; 143(3):250-259. PubMed ID: 31461700
[TBL] [Abstract][Full Text] [Related]
15. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.
JAMA; 1998 Apr 22-29; 279(16):1265-72. PubMed ID: 9565006
[TBL] [Abstract][Full Text] [Related]
16. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.
Magnani HN; Gallus A
Thromb Haemost; 2006 Jun; 95(6):967-81. PubMed ID: 16732376
[TBL] [Abstract][Full Text] [Related]
17. New treatment options for heparin-induced thrombocytopenia.
Ortel TL; Chong BH
Semin Hematol; 1998 Oct; 35(4 Suppl 5):26-34; discussion 35-6. PubMed ID: 9855181
[TBL] [Abstract][Full Text] [Related]
18. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran) in patients with heparin-induced thrombocytopenia.
Schenk JF; Pindur G; Stephan B; Mörsdorf S; Mertzlufft F; Kroll H; Wenzel E; Seyfert UT
Clin Appl Thromb Hemost; 2003 Jan; 9(1):25-32. PubMed ID: 12643320
[TBL] [Abstract][Full Text] [Related]
19. Treatment of 51 pregnancies with danaparoid because of heparin intolerance.
Lindhoff-Last E; Kreutzenbeck HJ; Magnani HN
Thromb Haemost; 2005 Jan; 93(1):63-9. PubMed ID: 15630492
[TBL] [Abstract][Full Text] [Related]
20. Heparin-induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation.
Lindhoff-Last E; Bauersachs R
Semin Thromb Hemost; 2002 Oct; 28(5):439-46. PubMed ID: 12420239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
